Defensins vs LL-37

Defensins vs LL-37 is a category-vs-molecule comparison: Defensins are a multi-gene family of alpha- and beta-defensins, while LL-37 is one 37-residue peptide cut from the only cathelicidin humans make. Both belong to innate immunity, neither is a product you simply take, and no therapeutic trial has compared them directly.

What is actually being compared?

Defensins describe many related human antimicrobial peptides; LL-37 names one exact molecule. That mismatch matters more than the usual AMP families compared chart admits. A defensin result may concern HNP-1 in neutrophils, HD5 in the intestine, or a beta-defensin at an epithelial barrier. An LL-37 result can at least point back to the same 37-residue sequence.

The common ground is real. Both are positively charged parts of innate defense, both can act against microbes, and both also communicate with immune cells. The useful question is therefore not “which peptide wins?” It is which level of biology fits the question: a diverse family or a defined cathelicidin fragment. The defensins profile covers the family member by member.

How do their structures differ?

Defensins are compact, disulfide-braced beta-sheet peptides; LL-37 is a flexible chain that forms an amphipathic alpha helix near membranes. Human alpha- and beta-defensins share six conserved cysteines, paired into three disulfide bonds. Those molecular cross-braces stabilize a largely beta-sheet fold, although the defensin sequences and exact cysteine connections vary by subgroup (PMC review).

LL-37 contains 37 amino acids and no cysteine. Around a membrane, hydrophobic residues face the lipid while charged residues face water, giving the peptide a helical working shape (PubMed review). That contrast makes “cathelicidin vs defensin” a structural distinction, not two labels for the same molecule. Both can disturb microbial membranes, but neither family name guarantees identical potency, target range, or behavior in living tissue.

Where are defensins and LL-37 stored?

Neutrophils separate these peptides into different cellular compartments. Neutrophil alpha-defensins are mature peptides packed into primary granules, also called azurophil granules. The hCAP-18 precursor of LL-37 sits in secondary, or specific, granules and is processed during release. The distinction is not decorative cell biology: location, precursor processing, and local concentration shape what reaches a microbe.

Defensins also extend beyond neutrophils. Paneth cells release alpha-defensins in the small intestine, while epithelial surfaces make beta-defensins. LL-37 is likewise expressed in epithelial tissues, but humans get that cathelicidin activity from one gene and its processed products. For the wider neighborhood, see the immune peptide hub. For the foundations, start with what antimicrobial peptides are.

Has a trial tested defensins vs LL-37 directly?

No therapeutic trial has compared defensins with LL-37 directly, and a clean family-versus-peptide trial is not a workable design. Researchers would first need to choose one defensin, one formulation, one route, and one condition. The experiment would then compare that named defensin with LL-37, not the defensin family as a whole. This page weighs separate evidence; it does not manufacture a shared contest.

The separate records are also uneven. Defensins have deep human observational biology and a real diagnostic use as measured alpha-defensin, but administered therapy remains a mechanistic hypothesis. The registered ORTD-1 defensin-mimetic study was withdrawn. LL-37 has entered small local-use studies, including a registered diabetic-foot-ulcer trial using 0.5 mg/mL cream twice weekly for four weeks (NCT04098562). That regimen does not establish an injectable, nasal, or general antimicrobial dose.

Can you take either one as a product?

Neither comparison arm is an ordinary therapeutic product. Defensins are endogenous family biology, not a standardized vial with one sequence or dose. LL-37 is also endogenous biology, although synthetic LL-37 is marketed using the language of immune defense and biofilms. A vendor label does not turn either into an approved treatment. This site sells neither, which makes the evidence boundary easier to state without squinting at a checkout button.

As of July 2026, no defensin therapeutic or LL-37 product is FDA-approved. FDA specifically lists compounded cathelicidin LL-37 among nominated bulk substances associated with potential significant safety risks and says it lacks enough safety information to know whether administration would harm humans (FDA). “Your body makes it” describes origin, not the safety of adding more from outside.

Which one fits which research goal?

Defensins fit questions about a broad, compartmentalized defense system; LL-37 fits questions requiring one defined sequence and a molecule-specific development record. Choose defensins for alpha-versus-beta family biology, mucosal defense, neutrophil primary granules, or alpha-defensin as a diagnostic marker. Choose LL-37 for alpha-helical membrane behavior, cathelicidin processing, or the limited human studies of local administration.

The honest ll-37 vs defensins verdict stops there. In defensins vs ll-37, LL-37 has moved farther into administered human research, but its headline antimicrobial use still lacks validating human trial evidence. Defensins have stronger evidence as native biology and measured biomarkers, yet weaker evidence as therapy. The shared comparison badge therefore uses the weaker mechanistic-hypothesis tier. The full tier definitions are in how we grade evidence; the by-goal picks below preserve the trade-off instead of crowning a universal winner.